Assembly Biosciences, Inc. (ASMB) Insider Trading
Over the last 3 months, ASMB insiders made 0 open-market buys and 1 sale, a net sale of -$674 (SEC Form 4). Over the last 6 months, 53 institutions increased and 33 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
1
Net (3m)
-$674
Insider trades by month Buys Sells
Nov
Dec
Apr
Oct
Mar
Jun
Context3-month price -1%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 18, 2026 | Bjorkquist Jeanette Mofficer: PFO and PAO | Sell | 29 | $23.25 |
| Jun 5, 2026 | Delaney William E IVofficer: Chief Scientific Officer | Grant | 14,000 | — |
| Jun 5, 2026 | Okazaki Jason Adirector, officer: CEO and President | Grant | 50,750 | — |
| Jun 5, 2026 | Bjorkquist Jeanette Mofficer: PFO and PAO | Grant | 3,500 | — |
| Jun 5, 2026 | ALTIG ANTHONY Edirector | Grant | 8,000 | $24.11 |
| Jun 5, 2026 | Consylman Ginadirector | Grant | 8,000 | $24.11 |
| Jun 5, 2026 | Houghton Michaeldirector | Grant | 8,000 | $24.11 |
| Jun 5, 2026 | Johnson-Pratt Lisadirector | Grant | 8,000 | $24.11 |
| Jun 5, 2026 | Mahony Susandirector | Grant | 8,000 | $24.11 |
| Jun 5, 2026 | McHutchison John Gdirector | Grant | 8,000 | $24.11 |
| Jun 5, 2026 | White Nicole Sofficer: Chief Manufacturing Officer | Grant | 14,000 | — |
| Jun 5, 2026 | Gaggar Anujofficer: Chief Medical Officer | Grant | 14,000 | — |
| May 27, 2026 | GILEAD SCIENCES, INC.10 percent owner | Grant | 471,698 | $26.50 |
| Mar 31, 2026 | Bjorkquist Jeanette Mofficer: PFO and PAO | Sell | 16 | $27.49 |
| Mar 31, 2026 | Bjorkquist Jeanette Mofficer: PFO and PAO | Grant | 6,500 | — |
| Mar 31, 2026 | Bjorkquist Jeanette Mofficer: PFO and PAO | Sell | 312 | $26.65 |
| Mar 31, 2026 | White Nicole Sofficer: Chief Manufacturing Officer | Grant | 26,000 | — |
| Mar 31, 2026 | White Nicole Sofficer: Chief Manufacturing Officer | Sell | 188 | $26.65 |
| Mar 31, 2026 | White Nicole Sofficer: Chief Manufacturing Officer | Sell | 9 | $27.49 |
| Mar 31, 2026 | Gaggar Anujofficer: Chief Medical Officer | Grant | 26,000 | — |
| Mar 31, 2026 | Delaney William E IVofficer: Chief Scientific Officer | Grant | 26,000 | — |
| Mar 31, 2026 | Okazaki Jason Adirector, officer: CEO and President | Grant | 94,250 | — |
| Oct 3, 2025 | GILEAD SCIENCES, INC.10 percent owner | Buy | 2,295,920 | $0.00 |
| Oct 3, 2025 | GILEAD SCIENCES, INC.10 percent owner | Buy | 1,147,960 | $21.60 |
| Jun 17, 2025 | Bjorkquist Jeanette Mofficer: PFO and PAO | Grant | 600 | $17.24 |
| Jun 17, 2025 | Bjorkquist Jeanette Mofficer: PFO and PAO | Grant | 300 | — |
| Jun 9, 2025 | RINGO WILLIAM Rdirector | Grant | 3,500 | $15.81 |
| Jun 9, 2025 | Johnson-Pratt Lisadirector | Grant | 3,500 | $15.81 |
| Jun 9, 2025 | McHutchison John Gdirector | Grant | 3,500 | $15.81 |
| Jun 9, 2025 | Mahony Susandirector | Grant | 3,500 | $15.81 |
Source: ASMB SEC Form 4 filings, latest Jun 18, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their ASMB positions over the last 6 months (SEC Form 13F).
Increased
53
New positions
38
Reduced
33
Sold out
18
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Unchanged | 4.5M | May 8, 2026 |
| GILEAD SCIENCES, INC. | Unchanged | 4.5M | Feb 12, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 1.7M | May 18, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Unchanged | 1.2M | Feb 17, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Unchanged | 1.2M | May 15, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | New Position | 1.2M | Feb 17, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 1.0M | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 1.0M | Feb 17, 2026 |
| COMMODORE CAPITAL LP | Unchanged | 1.0M | May 15, 2026 |
| COMMODORE CAPITAL LP | Unchanged | 1.0M | Feb 17, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 981K | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 838K | Feb 17, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | New Position | 665K | Feb 17, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | Unchanged | 665K | May 15, 2026 |
| POINT72 ASSET MANAGEMENT, L.P. | Increased | 601K | Feb 17, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.